Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant.
Read Article
Most Preoperative Breast MRIs Requested by Nononcologists
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—Preoperative breast magnetic resonance imaging (MRI) failed to influence clinical management in any subgroup of 257 patients with breast cancer, according to the results of a retrospective review that led one cancer center to discontinue the practice.
Read Article
HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—A new GP2 peptide vaccine was safe and reduced the rate of breast cancer recurrence in women with high-risk breast cancer in a phase 2 clinical trial.
Read Article
Noninvasive Imaging Technology Distinguishes Between Benign and Malignant Skin Lesions
By
Rosemary Frei, MSc
Melanoma
,
Solid Tumors
September 2014, Vol 5, No 7
Toronto, Ontario—New laser-based imaging technology differentiates malignant melanoma from other cancerous and benign skin lesions, according to a preliminary study presented at the 2014 Canadian Dermatology Association annual conference.
Read Article
Ramucirumab Improves Survival in Patients with Lung Cancer
By
Dana Butler
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—When added to chemotherapy (ie, docetaxel), the new monoclonal antibody ramucirumab improved overall survival (OS) compared with chemotherapy alone in patients with stage IV non–small-cell lung cancer (NSCLC), according to phase 3 trial results presented at the 2014 American Society of Clinical Oncology meeting.
Read Article
Necitumumab Extends Survival of Patients with Squamous Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL— Necitumumab, a human immunoglobulin G1 anti-EGFR monoclonal antibody, added to standard chemotherapy significantly improved survival compared with chemotherapy alone as first-line treatment of patients with stage IV non–small-cell lung cancer (NSCLC) of squamous histology.
Read Article
Association Between Indoor Tanning and Melanoma Confirmed in New Meta-Analysis
By
Rosemary Frei, MSc
Melanoma
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Toronto, Ontario—Going to more than 10 indoor tanning sessions over a person’s lifetime is associated with a 34% increased risk of developing melanoma, according to a new meta-analysis presented at the 2014 Canadian Dermatology Association annual meeting.
Read Article
Upfront Docetaxel Markedly Improves Survival
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—The upfront addition of docetaxel to androgen deprivation therapy (ADT) adds more than 1 year to overall survival (OS) compared with ADT alone in men with newly diagnosed hormone-sensitive prostate cancer, according to findings from a phase 3 study presented at the 2014 American Society of Clinical Oncology meeting.
Read Article
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Guidelines Target Brain Metastases in HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time.
Read Article
Page 10 of 16
5
6
7
8
9
10
11
12
13
14
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma